Study identifier:BY217/M2-112
ClinicalTrials.gov identifier:NCT00430729
EudraCT identifier:N/A
CTIS identifier:N/A
Effect of roflumilast on exacerbation rate in patients with chronic obstructive pulmonary disease. A 52 weeks double blind study with 500mcg roflumilast once daily versus placebo. Ratio-Study.
Chronic Obstructive Pulmonary Disease
Phase 3
No
Roflumilast
All
1100
Interventional
40 Years +
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Sept 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|